131 related articles for article (PubMed ID: 19953666)
1. A single pretreatment by zoledronic acid converts metastases from osteolytic to osteoblastic in the rat.
Nyangoga H; Blouin S; Libouban H; Baslé MF; Chappard D
Microsc Res Tech; 2010 Aug; 73(8):733-40. PubMed ID: 19953666
[TBL] [Abstract][Full Text] [Related]
2. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Saad F; McKiernan J; Eastham J
Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
[TBL] [Abstract][Full Text] [Related]
4. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
Green JR
Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
6. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
Saad F
Semin Oncol; 2002 Dec; 29(6 Suppl 21):19-27. PubMed ID: 12584691
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the effects of mixed osteolytic/osteoblastic metastasis on vertebral bone quality in a new rat model.
Wise-Milestone L; Akens MK; Rosol TJ; Hojjat SP; Grynpas MD; Whyne CM
J Orthop Res; 2012 May; 30(5):817-23. PubMed ID: 22025272
[TBL] [Abstract][Full Text] [Related]
8. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
[TBL] [Abstract][Full Text] [Related]
9. Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid.
Lamoureux F; Ory B; Battaglia S; Pilet P; Heymann MF; Gouin F; Duteille F; Heymann D; Redini F
Int J Cancer; 2008 Feb; 122(4):751-60. PubMed ID: 17960623
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
Corey E; Brown LG; Quinn JE; Poot M; Roudier MP; Higano CS; Vessella RL
Clin Cancer Res; 2003 Jan; 9(1):295-306. PubMed ID: 12538482
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
Rosen LS; Gordon D; Tchekmedyian S; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; de Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman JJ
J Clin Oncol; 2003 Aug; 21(16):3150-7. PubMed ID: 12915606
[TBL] [Abstract][Full Text] [Related]
12. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
Peyruchaud O; Winding B; Pécheur I; Serre CM; Delmas P; Clézardin P
J Bone Miner Res; 2001 Nov; 16(11):2027-34. PubMed ID: 11697798
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
Thudi NK; Martin CK; Nadella MV; Fernandez SA; Werbeck JL; Pinzone JJ; Rosol TJ
Prostate; 2008 Jul; 68(10):1116-25. PubMed ID: 18461562
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.
Montague R; Hart CA; George NJ; Ramani VA; Brown MD; Clarke NW
Eur Urol; 2004 Sep; 46(3):389-401; discussion 401-2. PubMed ID: 15306113
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Saad F; Lipton A
BJU Int; 2005 Nov; 96(7):964-9. PubMed ID: 16225510
[TBL] [Abstract][Full Text] [Related]
17. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
18. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
Lipton A; Colombo-Berra A; Bukowski RM; Rosen L; Zheng M; Urbanowitz G
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6397S-403S. PubMed ID: 15448038
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
20. The potential role of bisphosphonates in prostate cancer.
Oades GM; Coxon J; Colston KW
Prostate Cancer Prostatic Dis; 2002; 5(4):264-72. PubMed ID: 12627210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
